< Terug naar vorige pagina
Publicatie
The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer
Tijdschriftbijdrage - Tijdschriftartikel
Dendritic cell (DC) mono-immunotherapy has not been successful so far in ovarian cancer. The addition of a toll-like receptor (TLR) agonist has the potential to boost the innate immune system, in addition to the adoptive immune response initiated by DCs.
Tijdschrift: ANTICANCER RESEARCH
ISSN: 0250-7005
Issue: 11
Volume: 36
Pagina's: 5781 - 5792
Jaar van publicatie:2016
BOF-keylabel:ja
IOF-keylabel:ja
BOF-publication weight:0.1
CSS-citation score:1
Authors from:Higher Education
Toegankelijkheid:Open